The rho-kinase inhibitor H-1152P suppresses the wound-healing activities of human Tenon's capsule fibroblasts in vitro

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 5, 2007, Pages 2152-2161

  Tura, Aysegül ^a   Grisanti, Salvatore ^a   Petermeier, Katrin ^a   Henke Fahle, Sigrid ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; FIBRONECTIN; H 1125P; H 1152P; N ACETYLNEURAMINIC ACID; PHALLOIDIN; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2 METHYL 1 ((4 METHYL 5 ISOQUINOLINYL)SULFONYL)HOMOPIPERAZINE; 2-METHYL-1-((4-METHYL-5-ISOQUINOLINYL)SULFONYL)HOMOPIPERAZINE; ACTIN; ADDUCIN; CALMODULIN BINDING PROTEIN; COLLAGEN; DRUG DERIVATIVE; ENZYME INHIBITOR; KI 67 ANTIGEN; PROTEIN SERINE THREONINE KINASE; RHO KINASE; RHO-ASSOCIATED KINASE; SIGNAL PEPTIDE;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSKELETON; DOSE RESPONSE; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRESS FIBER; UPREGULATION; WOUND HEALING; CELL CULTURE; CELL MOTION; CELL SURVIVAL; CONNECTIVE TISSUE CELL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ACTINS; BLOTTING, WESTERN; CALMODULIN-BINDING PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN; CONNECTIVE TISSUE CELLS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FIBROBLASTS; FIBRONECTINS; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; PROTEIN-SERINE-THREONINE KINASES; WOUND HEALING;

EID: 34250223071     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1271     Document Type: Article

References (53)

1. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005;62:691-699.
2. Lachkar Y, Hamard P. Nonpenetrating filtering surgery. Curr Opin Ophthalmol. 2002;13:110-115.
3. Ofri R. Intraocular pressure and glaucoma. Vet Clin North Am Exot Anim Pract. 2002;5:391-406.
4. Chang MR, Cheng Q, Lee DA. Basic science and clinical aspects of wound healing in glaucoma filtering surgery. J Ocul Pharmacol Ther. 1998;14:75-95.
5. Khaw PT, Chang L, Wong TT, Mead A, Daniels JT, Cordeiro MF. Modulation of wound healing after glaucoma surgery. Curr Opin Ophthalmol. 2001;12:143-148.
6. Collignon NJ. Wound healing after glaucoma surgery: how to manage it? Bull Soc Beige Ophtalmol. 2005;295:55-59.
7. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314-346.
8. Khaw PT, Doyle JW, Sherwood MB, Grierson I, Schultz G, McGorray S. Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. Arch Ophthalmol. 1993;111: 263-267.
9. Crowston JG, Akbar AN, Constable PH, Occleston NL, Daniels JT, Khaw PT. Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci. 1998;39:449-454.
10. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol. 1992;114:544-553.
11. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol. 1992;110:1049-1050.
12. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40:2225-2234.
13. Grisanti S, Diestelhorst M, Heimann K, Krieglstein G. Cellular photoablation to control postoperative fibrosis in a rabbit model of filtration surgery. Br J Ophthalmol. 1999;83:1353-1359.
14. Grisanti S, Szurman P, Warga M, et al. Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci. 2005;46:191-196.
15. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 279:509-514.
16. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med. 2002;80:629-638.
17. Honjo M, Inatani M, Kido N, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol. 2001;119:1171-1178.
18. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137-144.
19. Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res. 2005;80:197-206.
20. Meyer-ter-Vehn T, Sieprath S, Katzenberger B, Gebhardt S, Grehn F, Schlunck G. Contractility as a prerequisite for TGF-beta-induced myofibroblast transdifferentiation in human Tenon fibroblasts. Invest Ophthalmol Vis Sci. 2006;47:4895-4904.
21. Jacobs M, Hayakawa K, Swenson L, et al. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem. 2006;281:260-268.
22. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212-7220.
23. Desmouliere A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. 2005;13:7-12.
24. Midwood KS, Williams LV, Schwarzbauer JE. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol. 2004;36:1031-1037.
25. Welch MP, Odland GF, Clark RA. Temporal relationships of F-actin bundle formation, collagen and fibronectin matrix assembly, and fibronectin receptor expression to wound contraction. J Cell Biol. 1990;110:133-145.
26. Nedelec B, Ghahary A, Scott PG, Tredget EE. Control of wound contraction: basic and clinical features. Hand Clin. 2000;16:289-302.
27. Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994;124:401-404.
28. Breitenlechner C, Gassel M, Hidaka H, et al. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure. 2003;11:1595-1607.
29. Ikenoya M, Hidaka H, Hosoya T, Suzuki M, Yamamoto N, Sasaki Y. Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J Neurochem. 2002;81:9-16.
30. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 2002;93:225-232.
31. Matsuoka Y, Li X, Bennett V. Adducin: structure, function and regulation. Cell Mol Life Sci. 2000;57:884-895.
32. Leif RC, Stein JH, Zucker RM. A short history of the initial application of anti-5-BrdU to the detection and measurement of S phase. Cytometry A. 2004;58:45-52.
33. Berg K, Hansen MB, Nielsen SE. A new sensitive bioassay for precise quantification of interferon activity as measured via the mitochondrial dehydrogenase function in cells (MTT-method). APMIS. 1990;98:156-162.
34. Mughal S, Al-Bader AA, Cuschieri A, Kharbat B. Ultrastructural localization of adenosine triphosphatase activity in HeLa cells at various stages of the cell cycle. Cell Tissue Res. 1987;250:349-354.
35. Raftopoulou M, Hall A. Cell migration: rho GTPases lead the way. Dev Biol. 2004;265:23-32.
36. Friedl P, Brocker EB. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci. 2000;57:41-64.
37. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446-456.
38. Worthylake RA, Lemoine S, Watson JM, Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol. 2001;154:147-160.
39. Yamada KM. Fibronectin peptides in cell migration and wound repair. J Clin Invest. 2000;105:1507-1509.
40. Wu C, Keivens VM, O'Toole TE, McDonald JA, Ginsberg MH. Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix. Cell. 1995;83:715-724.
41. Wierzbicka-Patynowski I, Schwarzbauer JE. The ins and outs of fibronectin matrix assembly. J Cell Sci. 2003;116:3269-3276.
42. Harris AK, Stopak D, Wild P. Fibroblast traction as a mechanism for collagen morphogenesis. Nature. 1981;290:249-251.
43. Porter RA, Brown RA, Eastwood M, Occleston NL, Khaw PT. Ultrastructural changes during contraction of collagen lattices by ocular fibroblasts. Wound Repair Regen. 1998;6:157-166.
44. Schiro JA, Chan BM, Roswit WT, et al. Integrin alpha 2 beta 1 (VLA-2) mediates reorganization and contraction of collagen matrices by human cells. Cell. 1991;67:403-410.
45. Klein CE, Dressel D, Steinmayer T, et al. Integrin alpha 2 beta 1 is upregulated in fibroblasts and highly aggressive melanoma cells in three-dimensional collagen lattices and mediates the reorganization of collagen I fibrils. J Cell Biol. 1991;115:1427-1436.
46. Gillery P, Maquart FX, Borel JP. Fibronectin dependence of the contraction of collagen lattices by human skin fibroblasts. Exp Cell Res. 1986;167:29-37.
47. Golubkov SP, Belkin VM, Rudneva SV, Terskikh W. Blood plasma fibronectin does not influence fibroblast-induced collagen gel contraction. Tsitologiia. 1990;32:499-503.
48. Asaga H, Kikuchi S, Yoshizato K. Collagen gel contraction by fibroblasts requires cellular fibronectin but not plasma fibronectin. Exp Cell Res. 1991;193:167-174.
49. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005;4: 387-398.
50. Howe AK. Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta. 2004;1692:159-174.
51. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J. 1996;15:510-519.
52. Ellerbroek SM, Wennerberg K, Burridge K. Serine phosphorylation negatively regulates RhoA in vivo. J Biol Chem. 2003;278:19023-19031.
53. Barkalow KL, Italiano JE Jr, Chou DE, Matsuoka Y, Bennett V, Hartwig JH. Alpha-adducin dissociates from F-actin and spectrin during platelet activation. J Cell Biol. 2003;161:557-570.